GlassScriptPhysician profile
Pauline Pepek
NPI 1427086628
$1,990.07
in general payments reported to CMS, 2019-2025
27 companies · $280 in 2025
The $280 reported for 2025 was more than what 83% of Adolescent Medicine (Pediatrics) providers received nationally (typical 2025 total: $99.31).
See the full distribution for Adolescent Medicine (Pediatrics)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $446 · 2020: $415 · 2021: $345 · 2022: $170 · 2023: $140 · 2024: $194 · 2025: $280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $614.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $614.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $497.54 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $193.19 | 2020-2025 | Gardasil 9, Vaxelis, M-M-R II |
| Sanofi Pasteur INC. | $153.77 | 2019-2025 | |
| Glaxosmithkline, LLC. | $129.80 | 2019-2022 | |
| Phadia US INC. | $129.28 | 2019-2025 | Immunocap |
| Genentech USA, INC. | $112.40 | 2019-2021 | |
| Kaleo, INC. | $82.42 | 2019-2024 | Auvi-Q |
| Cranial Technologies, INC | $78.07 | 2020-2024 | Doc Band |
| Alk-Abello, INC | $71.41 | 2025 | Neffy |
| Sanofi-Aventis U.S. LLC | $56.69 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $51.19 | 2025 | Neffy |
| Tris Pharma INC | $46.73 | 2022 | |
| Seqirus USA INC | $46.58 | 2020-2023 | Flucelvax Quadrivalent |
| Takeda Pharmaceuticals U.S.A., INC. | $46.30 | 2020 | |
| Mylan Pharmaceuticals INC. | $45.04 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertical Pharmaceuticals, LLC | $32.38 | 2019-2020 | |
| Arbor Pharmaceuticals, INC. | $29.44 | 2019 | |
| Lnhc, INC | $23.78 | 2025 | Zelsuvmi |
| Abbott Laboratories | $23.06 | 2019 | |
| Novartis Pharmaceuticals Corporation | $22.50 | 2019 | |
| Verrica Pharmaceuticals INC. | $20.74 | 2025 | Ycanth |
| Dermira, INC. | $20.60 | 2020 | |
| Neos Therapeutics, LP | $17.60 | 2025 | Cotempla Xr-Odt |
| Abbvie INC. | $17.11 | 2020 | |
| Nestle Healthcare Nutrition INC. | $16.46 | 2022 | |
| Mission Pharmacal Company | $14.24 | 2019 | |
| Qiagen, LLC | $11.75 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pauline Pepek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.